Shared on 06 Nov 25
Fair value Decreased 11%EQL: Expansion Into New Markets Will Drive Upside In Coming Years
Analysts have lowered their price target for EQL Pharma from SEK 90.00 to SEK 80.00. They cite revised expectations for valuation and a slightly higher discount rate, despite improved forecasts for revenue growth and profit margin.
Shared on 04 Aug 25
Fair value Increased 2.86%The upward revision in EQL Pharma’s price target reflects higher future P/E expectations despite stable profitability, indicating improved market confidence and raising the consensus fair value from SEK87.50 to SEK95.00. What's in the News EQL is expanding into Germany and the Netherlands by recruiting local experts to launch niche generics, aiming to replicate its Nordic strategy, with plans for future expansion into DACH and BeNeLux regions.